Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs around €58,500 in 2024. Unfortunately 99,8 % of our readers do not donate. If everyone reading this appeal made a small contribution, our fundraising campaign for 2024 would be over after a few days. This appeal is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute to support ADxS.org with your donation. Thank you very much!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V. Donations to ADxS e.V. are tax-deductible in Germany (up to €300, the remittance slip is sufficient as a donation receipt).

If you would prefer to make an active contribution, you can find ideas for Participation or active support here.

$45213 of $63500 - as of 2024-10-31
71%
ADxS.org Logo
ADxS.org Logo
Search Donations Addresses Recent changes ADHS-Forum Deutsche Version
Register

Already have an account? Login

Header Image
Reboxetine for ADHD

Sitemap

The ADxS.org project
Abstract from ADxS.org
Symptoms
Consequences of ADHD
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment: Guide and Effect size
Treatment: Medication for ADHD
Treatment: Medication for ADHD - Overview
Choice of medication for ADHD or ADHD with comorbidity
Dosing of medication for ADHD
Suitable medication for ADHD
Experimental medication for ADHD
Sleep disorder-related medication for ADHD
Appetite-enhancing medication for ADHD
Medication for ADHD in development
Less suitable medication for ADHD
Vitamins, minerals, dietary supplements for ADHD
Plant extracts for ADHD
Medication and drugs - the difference
Substance abuse with self-medication effect in ADHD
Non-drug treatment
Addresses
This and that about ADHD
Tests and surveys
Forum

Reboxetine for ADHD

Previous page Next page

Reboxetine is a noradrenaline reuptake inhibitor, as well as a weak serotonin reuptake inhibitor.

Trade names: Edronax (D, CH, A), Solcenx (D)

The active ingredient reboxetine is a noradrenergic drug which, according to individual reports, can be effective for ADHD. As an antidepressant, as it was actually intended to be, it was probably quite unsuccessful.

The updated European consensus on the diagnosis and treatment of ADHD (2018) names reboxetine as a possible alternative to atomoxetine for ADHD.1

There is evidence that reboxetine is effective for ADHD. However, there are only a few controlled studies. Reboxetine could be used primarily in adults without comorbidities.23

Reboxetine is not reimbursed by health insurance companies in Germany.

  1. Kooij, Bijlenga, Salerno, Jaeschke, Bitter, Balázs, Thome, Dom, Kasper, Filipe, Stes, Mohr, Leppämäki, Brugué, Bobes, Mccarthy, Richarte, Philipsen, Pehlivanidis, Niemela, Styr, Semerci, Bolea-Alamanac, Edvinsson, Baeyens, Wynchank, Sobanski, Philipsen, McNicholas, Caci, Mihailescu, Manor, Dobrescu, Krause, Fayyad, Ramos-Quiroga, Foeken, Rad, Adamou, Ohlmeier, Fitzgerald, Gill, Lensing, Mukaddes, Brudkiewicz, Gustafsson, Tania, Oswald, Carpentier, De Rossi, Delorme, Simoska, Pallanti, Young, Bejerot, Lehtonen, Kustow, Müller-Sedgwick, Hirvikoski, Pironti, Ginsberg, Félegeházy, Garcia-Portilla, Asherson (2018): Updated European Consensus Statement on diagnosis and treatment of adult ADHD, European Psychiatrie, European Psychiatry 56 (2019) 14–34, http://dx.doi.org/10.1016/j.eurpsy.2018.11.001, Seite 23, 7.4.7. ↥

  2. Ghanizadeh (2015): A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. PMID: 25415763. REVIEW ↥

  3. Riahi, Tehrani-Doost, Shahrivar, Alaghband-Rad (2010): Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. Hum Psychopharmacol. 2010 Nov;25(7-8):570-6. doi: 10.1002/hup.1158. ↥

Previous page Next page